Holen Sie sich die Stockscreener-App
1.14
1.72%
-0.02
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ONCT?
Forum
Prognose
Aktiensplit
Oncternal Therapeutics Inc Aktie (ONCT) Neueste Nachrichten
Oncternal Therapeutics Reports Q3 2024 Earnings - TipRanks
ONCT (Oncternal Therapeutics) 9-Day RSI : 33.20 (As of Nov. 20, 2024) - GuruFocus.com
Oncternal announces workforce reduction, executive changes - Investing.com
Oncternal Therapeutics to Cut Most of Its Workforce - MarketWatch
Oncternal Therapeutics Announces Workforce Reduction and Executive Changes - TipRanks
ONCT Stock Touches 52-Week Low at $1.03 Amid Market Challenges - Investing.com
StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT) - Defense World
Oncternal Therapeutics, Inc. Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - Marketscreener.com
Oncternal reports positive prostate cancer treatment results By Investing.com - Investing.com Australia
Oncternal reports positive prostate cancer treatment results - Investing.com India
Oncternal Therapeutics Announces Updated Safety and - GlobeNewswire
B-Cell Non-Hodgkin Lymphoma Pipeline Assessment 2024: Therapies, Clinical Trials, and Growth Prospects | Biegene, Oncternal Therapeutics, ZAI Lab, Pfizer, Xynomic Pharma, SystImmune Inc., Autolus - Barchart
Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.com - Defense World
ONCT Stock Touches 52-Week Low at $1.19 Amid Market Challenges - Investing.com Australia
Oncternal Therapeutics Inc (ONCT) Q2 2024 Earnings Call Highlights: Advancements in Clinical ... - Yahoo Finance Australia
Oncternal stock jumps 9% on FDA fast track designation - MSN
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.58% - MSN
ONCT Stock Touches 52-Week Low at $1.31 Amid Market Challenges - Investing.com Australia
ONCT Stock Touches 52-Week Low at $1.31 Amid Market Challenges By Investing.com - Investing.com South Africa
Recent Research Analysts’ Ratings Changes for Oncternal Therapeutics (ONCT) - Defense World
Omnicell Appoints Nnamdi Njoku as New COO - TipRanks
Oncolytics Biotech (TSE:ONC) Reaches New 12-Month Low at $1.20 - Defense World
ONON’s Stock Market Adventure: 85.15% YTD Growth Amidst Volatility - The InvestChronicle
Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer - Silicon UK
ONMD’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
Levi & Korsinsky Notifies Shareholders of Outset Medical, - GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Outset Medical, Inc.OM - PR Newswire
Fred Alger Management LLC Has $44.73 Million Position in On Holding AG (NYSE:ONON) - MarketBeat
Layoff Tracker: Bluebird Bio to Cut 25% of Workforce and More News - BioSpace
Recent Insider Activity Suggests Potential Gains for Outset Medical Inc (OM) - Knox Daily
On Holding's Options Frenzy: What You Need to Know - Benzinga
This Option Provides Gains By Coasting With On Running Shoes - Investor's Business Daily
ONON’s valuation metrics: A comprehensive analysis - US Post News
OM Stock on the Rise: A Promising Investment - The InvestChronicle
Was Outset Medical Inc (OM)’s session last reading good? - US Post News
Promising Progress in Oncology as Cancer Deaths Decline and Research Grows - Baystreet.ca
Views of Wall Street’s Leading Experts on Onconetix Inc - SETE News
Financial Metrics Unveiled: Outset Medical Inc (OM)’s Key Ratios in the Spotlight - The Dwinnex
Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com - Defense World
Outset Medical (OM) Shares Down 94% Since Disclosing FDA - GlobeNewswire
On Holding Options Trading: A Deep Dive into Market Sentiment - Benzinga
ON (NYSE:ONON) Rating Increased to Neutral at Bank of America - MarketBeat
OM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Outset Medical, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Onsemi Could Be Set Up For a Solid Rebound: Here's Why - MarketBeat
Kayne Anderson Rudnick Investment Management LLC Boosts Stock Position in On Holding AG (NYSE:ONON) - MarketBeat
Onconetix (NASDAQ:ONCO) Shares to Reverse Split on Tuesday, September 24th - Defense World
Bradley Foster & Sargent Inc. CT Increases Stock Position in On Holding AG (NYSE:ONON) - Defense World
Onsemi (NASDAQ:ON) Holdings Raised by Argent Trust Co - Defense World
Why Onconetix (ONCO) Shares Are Down 27% - Benzinga
Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders - GlobeNewswire
On Holding AG (NYSE:ONON) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Oncolytics Biotech reports positive results from breast cancer study | 2024-09-19 | Investing News - Stockhouse Publishing
Recent Breakthroughs in Cancer Research Could Impact These Key Companies - Baystreet.ca
Oncolytics Phase 2 breast cancer data ‘compelling, says H.C. Wainwright - TipRanks
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech’s Promising Breast Cancer Study - TipRanks
Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study - PR Newswire
ON (NYSE:ONON) Reaches New 1-Year High After Analyst Upgrade - Defense World
On Holding AG shares get price target boost, buy rating from Stifel - Investing.com
Investing in On Holding AG (ONON) Is Getting More Attractive - Knox Daily
J.W. Cole Advisors Inc. Cuts Stock Holdings in On Holding AG (NYSE:ONON) - Defense World
ON (NYSE:ONON) Hits New 1-Year High After Analyst Upgrade - MarketBeat
B-Cell Lymphomas Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024 - The Globe and Mail
1.89%
2.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):